NMN (Nicotinamide Mononucleotide) Research Overview (also known as β-Nicotinamide mononucleotide, β-NMN, Nicotinamide ribotide, Nicotinamide-1-β-D-ribofuranoside 5′-monophosphate)
NMN is nicotinamide mononucleotide, a vitamin B3-related molecule involved in the body's production of NAD+. It is studied in metabolism, mitochondrial function and aging biology. The page distinguishes laboratory and animal findings from generally small, short human trials examining metabolic markers, vascular function and physical performance.
What Is NMN (Nicotinamide Mononucleotide)?
Nicotinamide mononucleotide, usually abbreviated NMN, is a phosphorylated nucleotide derived from the vitamin B3 family. It exists in alpha and beta anomeric forms, although the beta form is the biologically relevant form generally discussed in nutritional and aging research. NMN is an endogenous intermediate in the salvage pathway that converts nicotinamide into NAD+, a central metabolic cofactor. NAD+ participates in oxidation-reduction reactions and also serves as a substrate for enzymes such as sirtuins, poly(ADP-ribose) polymerases, and CD38. Because tissue NAD+ concentrations tend to change with age, NMN has become a research compound of interest in studies of metabolism, mitochondrial biology, DNA-damage responses, inflammation, and functional aging.
NMN is not established as a lifespan-extending drug, and it should not be interpreted as a proven anti-aging treatment. Most mechanistic and lifespan findings have come from cell and animal models, while human trials have generally been short, small, and focused on pharmacokinetics, safety, metabolic markers, vascular function, or physical performance. Oral NMN has been the principal route investigated in published human work. Sublingual products are commercially available, but comparative evidence demonstrating superior absorption or clinical benefit over oral administration is limited.
Quick Reference
Member reference tables summarize the compound's research parameters.
A controlled study in overweight or obese postmenopausal women with prediabetes found that 10 weeks of NMN increased skeletal-muscle insulin sensitivity.
NAD+ precursor activity
NMN is an intermediate in NAD+ biosynthesis; oral administration has increased circulating NAD-related metabolites in human studies.
Physical Performance
Emerging Evidence
Aerobic capacity
Small human trials, including protocols paired with exercise training, have reported improvements in selected walking or aerobic-performance measures; findings require replication.
Muscle NAD+ metabolism
Research suggests NMN may alter NAD+ metabolite handling in skeletal muscle, though functional effects vary by population and study design.
Healthy Aging Biology
Preliminary Data
Age-related NAD+ decline
Declining NAD+ availability is implicated in several age-associated pathways, but evidence that NMN supplementation slows human aging remains insufficient.
Cellular energy pathways
Preclinical work links NMN-mediated NAD+ restoration with sirtuin and mitochondrial pathways; these mechanistic findings should not be interpreted as established clinical outcomes.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The listed research text specifies choosing products with a recent, lot-matched COA identifying NMN content, analytical method, testing laboratory, and batch number.
Verified Marker
HPLC or equivalent purity testing
A credible COA should report chromatographic purity and identify the NMN form, ideally with a stated assay result rather than an unsupported purity claim.
Verified Marker
Independent contaminant screening
Prefer documented third-party testing for heavy metals and relevant microbial contaminants, especially for powders and high-dose capsules.
Acceptable Range
Accurate dosage form and labeling
Capsules, tablets, and sublingual products should state NMN amount per unit, serving size, excipients, storage instructions, and manufacturer contact information.
Quality Concern
Unverifiable purity or implausible claims
The listed research text specifies avoiding products without a batch-specific COA, products using only generic laboratory reports, or brands making guaranteed anti-aging, disease-treatment, or pharmaceutical-equivalence claims.
Safety evaluation of nicotinamide mononucleotide administration: a randomized, double-blind, placebo-controlled study. Irie, J., Inagaki, E., Fujita, M., et al., 2020, Endocrine Journal